BRPI0919937A2 - composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina - Google Patents

composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina

Info

Publication number
BRPI0919937A2
BRPI0919937A2 BRPI0919937A BRPI0919937A BRPI0919937A2 BR PI0919937 A2 BRPI0919937 A2 BR PI0919937A2 BR PI0919937 A BRPI0919937 A BR PI0919937A BR PI0919937 A BRPI0919937 A BR PI0919937A BR PI0919937 A2 BRPI0919937 A2 BR PI0919937A2
Authority
BR
Brazil
Prior art keywords
imidazoquinoline
enhancing
compound
adjuvant activity
adjuvant
Prior art date
Application number
BRPI0919937A
Other languages
English (en)
Inventor
David Johnson
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0919937A2 publication Critical patent/BRPI0919937A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BRPI0919937A 2008-10-24 2009-10-23 composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina BRPI0919937A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10821008P 2008-10-24 2008-10-24
US22422609P 2009-07-09 2009-07-09
US22993309P 2009-07-30 2009-07-30
PCT/US2009/061867 WO2010048520A1 (en) 2008-10-24 2009-10-23 Lipidated imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0919937A2 true BRPI0919937A2 (pt) 2016-02-16

Family

ID=42119702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919937A BRPI0919937A2 (pt) 2008-10-24 2009-10-23 composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina

Country Status (23)

Country Link
US (2) US8624029B2 (pt)
EP (1) EP2341933B1 (pt)
JP (1) JP5695569B2 (pt)
KR (1) KR20110077004A (pt)
CN (1) CN102264394B (pt)
AU (1) AU2009308278B2 (pt)
BR (1) BRPI0919937A2 (pt)
CA (1) CA2741291A1 (pt)
CY (1) CY1119981T1 (pt)
DK (1) DK2341933T3 (pt)
ES (1) ES2656813T3 (pt)
HR (1) HRP20180063T1 (pt)
HU (1) HUE036531T2 (pt)
IL (1) IL212417A (pt)
LT (1) LT2341933T (pt)
MX (1) MX2011004249A (pt)
NO (1) NO2341933T3 (pt)
PL (1) PL2341933T3 (pt)
PT (1) PT2341933T (pt)
SI (1) SI2341933T1 (pt)
TR (1) TR201802083T4 (pt)
WO (1) WO2010048520A1 (pt)
ZA (1) ZA201103590B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
PL2491035T3 (pl) 2009-10-22 2018-01-31 Gilead Sciences Inc Pochodne puryny lub deazapuryny przydatne do leczenia (między innymi) infekcji wirusowych
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
CA2810011A1 (en) * 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US20140242112A1 (en) * 2012-11-30 2014-08-28 Glaxosmithkline Biologicals S.A. Novel vaccine
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
WO2015023958A1 (en) * 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
BR112017000528A2 (pt) 2014-07-11 2017-11-14 Gilead Sciences Inc moduladores dos receptores toll-like para o tratamento do hiv
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
BE1023340B1 (fr) 2014-11-13 2017-02-08 Glaxosmithkline Biologicals S.A. Composes
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
EP3355933B1 (en) 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
PL3868741T3 (pl) 2015-10-07 2024-01-29 Sumitomo Pharma Co., Ltd. Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu
CA3008054A1 (en) 2015-12-14 2017-06-22 Glaxosmithkline Biologicals S.A. Phospholipidation of imidazoquinolines and oxoadenines
WO2017102652A1 (en) * 2015-12-14 2017-06-22 Glaxosmithkline Biologicals S.A. Pegylated imidazoquinolines as tlr7 and tlr8 agonists
US9966457B2 (en) * 2016-03-18 2018-05-08 Globalfoundries Inc. Transistor structure with varied gate cross-sectional area
BE1024865B1 (fr) * 2016-09-07 2018-07-31 Glaxosmithkline Biologicals Sa Derives d'imidazoquinoleine
US11253476B2 (en) 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
CN111757755A (zh) 2017-12-21 2020-10-09 大日本住友制药株式会社 包含tlr7激动剂的组合药物
CN112839673A (zh) 2018-07-23 2021-05-25 日本国立感染症研究所所长代表之日本国 包含流感疫苗的组合物
KR20220018503A (ko) 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
CN112778372A (zh) * 2019-11-11 2021-05-11 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
US20230373997A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Imdq-peg-chol adjuvant and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285420B6 (cs) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
CA2495570C (en) * 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
ES2544477T3 (es) * 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060051374A1 (en) * 2004-04-28 2006-03-09 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
BRPI0515316A (pt) * 2004-09-14 2008-07-15 Chiron Corp compostos de imidazoquinolina
CA2634349A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases

Also Published As

Publication number Publication date
ES2656813T3 (es) 2018-02-28
WO2010048520A1 (en) 2010-04-29
PT2341933T (pt) 2018-02-13
EP2341933A4 (en) 2012-03-14
CY1119981T1 (el) 2018-12-12
IL212417A (en) 2017-01-31
CN102264394A (zh) 2011-11-30
EP2341933A1 (en) 2011-07-13
JP5695569B2 (ja) 2015-04-08
PL2341933T3 (pl) 2018-04-30
SI2341933T1 (en) 2018-03-30
KR20110077004A (ko) 2011-07-06
US8624029B2 (en) 2014-01-07
ZA201103590B (en) 2012-10-31
DK2341933T3 (da) 2018-01-29
AU2009308278B2 (en) 2014-11-27
AU2009308278A1 (en) 2010-04-29
US20110282061A1 (en) 2011-11-17
NO2341933T3 (pt) 2018-04-21
MX2011004249A (es) 2011-07-20
IL212417A0 (en) 2011-06-30
HUE036531T2 (hu) 2018-07-30
CN102264394B (zh) 2014-01-01
HRP20180063T1 (hr) 2018-02-23
CA2741291A1 (en) 2010-04-29
JP2012506865A (ja) 2012-03-22
TR201802083T4 (tr) 2018-03-21
LT2341933T (lt) 2018-04-10
US20140323731A1 (en) 2014-10-30
EP2341933B1 (en) 2017-11-22
US8946421B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
BRPI0919937A2 (pt) composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
BRPI0906906A2 (pt) Método para preparar um composto e composto
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BRPI0923748A2 (pt) Método para a preparação de dióis
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BR112013007604A8 (pt) composto, composição, método para controlar um nematoide parasitário e semente tratada
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
CO6781493A2 (es) Inhibidores de la faah
BRPI0919116A2 (pt) método
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BRPI0917714A2 (pt) método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
DK2313489T3 (da) Fremstillingsmetode
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BR112014013614A2 (pt) composição antimicrobiana, método para desinfetar uma superfície e uso de uma composição
BR112013009590A2 (pt) composto, composição fungicida e método
BR112014013601A2 (pt) composição antimicrobiana sólida, método para desinfetar uma superfície e uso de uma composição
BRPI0916597A2 (pt) Método
BR112014012759A8 (pt) composto, composição e método para tratamento
BR112012021152A8 (pt) arranjo de fixação, cadeia de compartimento de um poço incluindo-o e método para fixação do mesmo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.